分子印迹聚合物在恶性肿瘤诊疗方面的应用  

Application of Molecularly Imprinted Polymers in the Diagnosis and Treatment of Malignant Tumors

作　　者：李世红 金玉顺[1] 温振国 刘若凡 伍一波[1] LI Shi-hong;JIN Yu-shun;WEN Zhen-guo;LIU Ruo-fan;WU Yi-bo(Beijing Key Laboratory of Special Elastomer Composites,School of New Materials and Chemical Engineering,Beijing Institute of Petrochemical Technology,Beijing 102617,China)

机构地区：[1]北京石油化工学院新材料与化工学院特种弹性体复合材料北京市重点实验室,北京102617

出　　处：《高分子通报》2023年第5期539-550,共12页Polymer Bulletin

基　　金：国家自然科学基金项目(52073033)。

摘　　要：近年来,癌症的发病率和致死率依然处于不断上升的状态,癌症已经成为威胁全球人类健康的最主要疾病之一。癌症的诊断和治疗往往因无法特异性靶向肿瘤细胞而受到阻碍,分子印迹聚合物是一种合成受体,具有针对目标分子量身定制的识别位点,因此分子印迹聚合物可以对肿瘤细胞进行选择性识别。目前,分子印迹聚合物被广泛应用于制备负载抗癌药物的载体材料方面,成为一种诊疗一体化的特异性靶向恶性肿瘤的工具。本文综述了分子印迹聚合物在恶性肿瘤诊断和治疗方面的应用(包括以抗癌药物为模板、以可以靶向肿瘤标志物的表位为模板、以抗癌药物和可以靶向肿瘤标志物的表位为双模板以及以蛋白质分子建模为模板制备的分子印迹聚合物)。另外,分子印迹聚合物还可以通过阻断人类表皮生长因子受体-2(HER2)的信号通路来抑制乳腺癌的生长。最后,强调了分子印迹聚合物在恶性肿瘤应用的当前挑战和未来前景。The incidence and mortality of cancer kept rising for years.Cancer has become one of the most serious diseases threatening human health in the world.Due to the difficulty of precisely targeting the tumor cells,diagnosis and treatment of cancer is always a problem.Molecularly imprinted polymer(MIP)is a kind of synthetic receptor with tailored recognizable sites on its molecule.It provides a way to selectively recognize tumor cells.Presently,molecular imprinted polymers are widely used in the preparation of anticancer drug carrier materials.It has become a specific targeting tool for the diagnosis and treatment of cancer.The application of molecular imprinted polymer in the diagnosis and treatment of malignant tumors(including using anticancer drugs as the templates,and templates based on a protein molecule modeling)was reviewed in this paper.In addition,molecular imprinted polymers also inhibit breast cancer growth by blocking the human epidermal growth factor receptor-2(HER2)transducing pathway.The current challenges and future prospects of molecular imprinted polymer application in cancer therapy are also discussed.

关 键 词：恶性肿瘤 分子印迹聚合物 肿瘤标志物 抗癌药物 诊疗一体化 

分 类 号：O631.3[理学—高分子化学] TQ460.4[理学—化学]